Skip to main
  1. Stocks
  2. CryoPort
  3. Forecast
CYRX

CryoPort (CYRX) Stock Forecast & Price Target

CryoPort (CYRX) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CryoPort is benefiting from an inflecting cell and gene therapy market, where commercial therapies are expanding quickly and management cited 23 commercial therapies supported, 788 clinical trials, and 20% commercial revenue growth in 3Q26. Revenue rose 14% y/y to $50.2M, led by 18% growth in Life Sciences Services, while adjusted EBITDA turned positive at $1.1M versus -$0.6M in 3Q25, showing operating leverage as demand improves. The outlook is further supported by a strong cash position of about $393.1M, new global supply chain centers in California and France, and upcoming approvals that could deepen visibility and lift higher-margin service revenue.

Bears say

CryoPort is challenged by slowing revenue growth if cell and gene therapy approvals come in below expectations, which would also pressure margins and profitability across its heavily services-driven business. Its operating model carries meaningful execution risk because cryogenic shipments must meet rigorous standards, while third-party carrier dependence, lengthy customer onboarding, and reliance on third-party software can disrupt service delivery, damage reputation, and expose the company to litigation and lost revenues. Competitive and regulatory pressures remain elevated, and continued weakness in MVE freezer demand suggests that even the Life Sciences Products segment may face ongoing headwinds.

CryoPort (CYRX) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.

CryoPort (CYRX) Analyst Forecast & Price Prediction

Get the latest CryoPort (CYRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CryoPort (CYRX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CryoPort (CYRX) Forecast

Analysts have given CryoPort (CYRX) a Strong Buy based on their latest research and market trends.

According to 5 analysts, CryoPort (CYRX) has a Strong Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CryoPort (CYRX)


CryoPort (CYRX) Analyst Forecast & Price Prediction

Get the latest CryoPort (CYRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CryoPort (CYRX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CYRX stock data and trends